MX2024007906A - Sal farmaceuticamente aceptable y forma cristalina del agonista receptor glp-1 y metodo de preparacion del mismo. - Google Patents
Sal farmaceuticamente aceptable y forma cristalina del agonista receptor glp-1 y metodo de preparacion del mismo.Info
- Publication number
- MX2024007906A MX2024007906A MX2024007906A MX2024007906A MX2024007906A MX 2024007906 A MX2024007906 A MX 2024007906A MX 2024007906 A MX2024007906 A MX 2024007906A MX 2024007906 A MX2024007906 A MX 2024007906A MX 2024007906 A MX2024007906 A MX 2024007906A
- Authority
- MX
- Mexico
- Prior art keywords
- pharmaceutically acceptable
- acceptable salt
- crystalline form
- glp
- receptor agonist
- Prior art date
Links
- 150000003839 salts Chemical class 0.000 title abstract 3
- 229940089838 Glucagon-like peptide 1 receptor agonist Drugs 0.000 title abstract 2
- 239000003877 glucagon like peptide 1 receptor agonist Substances 0.000 title abstract 2
- 238000002360 preparation method Methods 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- RWTNPBWLLIMQHL-UHFFFAOYSA-N fexofenadine Chemical group C1=CC(C(C)(C(O)=O)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 RWTNPBWLLIMQHL-UHFFFAOYSA-N 0.000 abstract 1
- BDAGIHXWWSANSR-UHFFFAOYSA-N formic acid Substances OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
- C07C215/02—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C215/04—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated
- C07C215/06—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated and acyclic
- C07C215/08—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated and acyclic with only one hydroxy group and one amino group bound to the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
- C07C215/02—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C215/04—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated
- C07C215/06—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated and acyclic
- C07C215/10—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated and acyclic with one amino group and at least two hydroxy groups bound to the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
- C07C215/02—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C215/04—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated
- C07C215/06—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated and acyclic
- C07C215/12—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated and acyclic the nitrogen atom of the amino group being further bound to hydrocarbon groups substituted by hydroxy groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C279/00—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
- C07C279/04—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to acyclic carbon atoms of a carbon skeleton
- C07C279/14—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to acyclic carbon atoms of a carbon skeleton being further substituted by carboxyl groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
- C07C309/01—Sulfonic acids
- C07C309/28—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
- C07C309/29—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings
- C07C309/30—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings of six-membered aromatic rings substituted by alkyl groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C59/235—Saturated compounds containing more than one carboxyl group
- C07C59/245—Saturated compounds containing more than one carboxyl group containing hydroxy or O-metal groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C59/235—Saturated compounds containing more than one carboxyl group
- C07C59/245—Saturated compounds containing more than one carboxyl group containing hydroxy or O-metal groups
- C07C59/255—Tartaric acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Diabetes (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111584574 | 2021-12-23 | ||
| PCT/CN2022/141418 WO2023116882A1 (zh) | 2021-12-23 | 2022-12-23 | 一种glp-1受体激动剂的可药用盐、结晶形式及其制备方法 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2024007906A true MX2024007906A (es) | 2024-07-10 |
Family
ID=86901360
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2024007906A MX2024007906A (es) | 2021-12-23 | 2022-12-23 | Sal farmaceuticamente aceptable y forma cristalina del agonista receptor glp-1 y metodo de preparacion del mismo. |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20250049777A1 (enExample) |
| EP (2) | EP4455141B1 (enExample) |
| JP (1) | JP2024547113A (enExample) |
| KR (1) | KR20240125003A (enExample) |
| CN (1) | CN118434730A (enExample) |
| AU (1) | AU2022418658A1 (enExample) |
| CA (1) | CA3241670A1 (enExample) |
| DK (1) | DK4455141T3 (enExample) |
| MX (1) | MX2024007906A (enExample) |
| TW (1) | TW202328114A (enExample) |
| WO (1) | WO2023116882A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2024340407A1 (en) | 2023-09-14 | 2026-04-23 | Ascletis Pharma (China) Co., Limited | Glp-1r agonist and therapeutic method thereof |
| WO2025109387A1 (en) | 2023-11-24 | 2025-05-30 | Ascletis Pharma (China) Co., Limited | Glp-1r agonist and therapeutic method thereof |
| TW202535353A (zh) * | 2024-01-09 | 2025-09-16 | 大陸商山東盛迪醫藥有限公司 | 一種ｇｌｐ－１ｒ激動劑醫藥組成物及其應用 |
| WO2025189141A1 (en) | 2024-03-08 | 2025-09-12 | Annapurna Bio, Inc. | Methods for treating obesity and increasing weight loss |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10934279B2 (en) * | 2018-06-13 | 2021-03-02 | Pfizer Inc. | GLP-1 receptor agonists and uses thereof |
| CU20210042A7 (es) * | 2018-11-22 | 2022-01-13 | Qilu Regor Therapeutics Inc | Compuestos agonistas de glp-1r y composiciones farmacéuticas que lo contienen |
| EP4166142A4 (en) * | 2020-06-10 | 2024-06-26 | Medshine Discovery Inc. | Methyl-substituted benzobisoxazole compound and use thereof |
| CN119930605A (zh) * | 2020-09-01 | 2025-05-06 | 江苏恒瑞医药股份有限公司 | 稠合咪唑类衍生物、其制备方法及其在医药上的应用 |
| WO2022228490A1 (zh) * | 2021-04-30 | 2022-11-03 | 上海翰森生物医药科技有限公司 | 多环类衍生物调节剂、其制备方法和应用 |
-
2022
- 2022-12-23 EP EP22910193.6A patent/EP4455141B1/en active Active
- 2022-12-23 CN CN202280085412.2A patent/CN118434730A/zh active Pending
- 2022-12-23 EP EP26158421.3A patent/EP4732838A2/en active Pending
- 2022-12-23 US US18/721,934 patent/US20250049777A1/en active Pending
- 2022-12-23 JP JP2024537986A patent/JP2024547113A/ja active Pending
- 2022-12-23 KR KR1020247024147A patent/KR20240125003A/ko active Pending
- 2022-12-23 WO PCT/CN2022/141418 patent/WO2023116882A1/zh not_active Ceased
- 2022-12-23 MX MX2024007906A patent/MX2024007906A/es unknown
- 2022-12-23 AU AU2022418658A patent/AU2022418658A1/en active Pending
- 2022-12-23 TW TW111149827A patent/TW202328114A/zh unknown
- 2022-12-23 CA CA3241670A patent/CA3241670A1/en active Pending
- 2022-12-23 DK DK22910193.6T patent/DK4455141T3/da active
Also Published As
| Publication number | Publication date |
|---|---|
| WO2023116882A1 (zh) | 2023-06-29 |
| DK4455141T3 (da) | 2026-04-27 |
| KR20240125003A (ko) | 2024-08-19 |
| AU2022418658A1 (en) | 2024-07-11 |
| CN118434730A (zh) | 2024-08-02 |
| CA3241670A1 (en) | 2023-06-29 |
| TW202328114A (zh) | 2023-07-16 |
| EP4455141A4 (en) | 2025-04-09 |
| JP2024547113A (ja) | 2024-12-26 |
| EP4455141A1 (en) | 2024-10-30 |
| US20250049777A1 (en) | 2025-02-13 |
| EP4455141B1 (en) | 2026-03-25 |
| EP4732838A2 (en) | 2026-04-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA3241670A1 (en) | Pharmaceutically acceptable salt and crystalline form of glp-1 receptor agonist and preparation method therefor | |
| MX2024007907A (es) | Forma cristalina del agonista del receptor de peptido 1 similar al glucagon y metodo de preparacion del mismo. | |
| ES3066183T3 (en) | 2-(((2,3-dihydrobenzo[b][1,4]dioxan-5-yl)piperidin-1-yl)methyl)-1-((oxetan-2-yl)methyl)-1h-benzo[d]imidazole-6-carboxylic acid derivatives and similar compounds as glp-1 modulators for the treatment of diabetes | |
| CA2419552C (en) | Substituted pyrazoles | |
| MX2023002979A (es) | Formas cristalinas y amorfas de un compuesto para la degradacion dirigida del receptor de estrogenos. | |
| CY1108786T1 (el) | Ν-αρυλσουλφονυλ-3-υποκατεστημενα ινδολια που εχουν συναφεια υποδοχεα σεροτονινης, μεθοδος για τη παρασκευη αυτων και φαρμακευτικη συνθεση περιεχουσα αυτα | |
| MY194461A (en) | N-[2-(1-benzylpiperidin-4-yl)4-(pyrazin-2-yl)-piperazine-1-carboxamide derivatives and related compounds as muscarinic receptor 4 (m4) antagonists for treating neurological diseases | |
| US20110281840A1 (en) | N-substituted saturated heterocyclic sulfone compounds with cb2 receptor agonistic activity | |
| AR091771A2 (es) | Compuesto 2,3-dihidro-6-nitroimidazo[2,1-b]oxazol | |
| MX2025011326A (es) | Formas polimorficas y sales de un agonista de glp-1r | |
| JP2007528883A5 (enExample) | ||
| JP2006501273A5 (enExample) | ||
| CY1125531T1 (el) | Μεθοδος παρασκευης της 5-[[4-[2-[5-(1- υδροξυαιθυλ)-2-πυριδι-νυλ]αιθοξυ]φαινυλ]μεθυλ]- 2,4-θειαζολιδινεδιονη και των αλατων της | |
| BR0309277A (pt) | Processo para preparação de um composto | |
| MX2022011582A (es) | Formas cristalinas de un agonista del receptor farnesoide x. | |
| Liu et al. | Pyrrolidine-3-carboxylic acids as endothelin antagonists. 3. Discovery of a potent, 2-nonaryl, highly selective ETA antagonist (A-216546) | |
| PE20010954A1 (es) | Bencimidazoles, su preparacion y su empleo como medicamentos | |
| RU2007119638A (ru) | Новые индольные или бензимидазольные производные | |
| NZ585428A (en) | Use of immunomodulatory compounds for the treatment of disorders associated with endothelial dysfunction | |
| RU2008129625A (ru) | Замещенные производные оксазола с аналгетическим действием | |
| CO5261525A1 (es) | Forma poliformica de un antagonista de los receptores de las taquiquininas . | |
| UY27694A1 (es) | Forma de administración para la aplicación oral de éster etilico del ácido 3-((2-((4- (hexiloxicarbonilamino-amino-metil)- fenilamino)metil)-1-metil-1 h -bencimidazol-5-carbonil)-piridin-2il-amino)-procíonico y las sales del mismo. | |
| JP2004525983A5 (enExample) | ||
| MY199479A (en) | Pharmaceutical composition and method for preparing same | |
| DE602006010329D1 (de) | Verfahren zur herstellung eines indolon-derivats |